HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer's Consumer Health Struggles Continue In Q1, But The Firm Insists It's On The Right Track

Executive Summary

Bayer Consumer Health's sales declined at a single-digit rate in the first quarter of 2019, as the business continued to battle challenges in Europe and the US. Undeterred by this slow start to the year, the German firm says Consumer Health's performance will begin to turnaround in the coming months. 

You may also be interested in...



Bayer Hopes Consumer Health Woes Are In Rear View Mirror As Business Returns To Growth

Bayer is starting to see green shoots of recovery after a prolonged period of declining sales and earnings at its Consumer Health business. Turnover improved by 2% in the second quarter, driven by gains in Europe and Latin America. 

Q2 Consumer Health Earnings Preview: GSK And Bayer

GSK is looking to ramp up growth and focus its portfolio as its consumer health JV with Pfizer edges ever closer to completion. Meanwhile, Bayer is hoping to see the green shoots of recovery in Q2 with its Consumer Health turnaround plan now in full swing. 

Bayer Pares Dr. Scholl's In Latest Step Toward Core Consumer Portfolio

Bayer follows through on plans to divest Dr. Scholl’s after selling Coppertone business in May to focus on consumer lines such as Aleve oral analgesics, Claritin allergy treatments and Bayer Aspirin. Private equity firm Yellow Wood Partners creating stand-alone company to operate Dr. Scholl's.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel